These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2327767)

  • 41. [In vitro and in vivo activity of a combination of clavulanic acid and amoxicillin against Klebsiella pneumoniae producing extended broad-spectrum betalactamase (CTX-1, SHV-3, SHV-4)].
    Migueres ML; Ronco E; Guenounou M; Philippon A
    Pathol Biol (Paris); 1989 May; 37(5):397-401. PubMed ID: 2674869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study of amoxycillin and amoxycillin/clavulanic acid in lower respiratory infections.
    Mehta AP; Phutane L; Patel MH; Rupwate RU; Kamat SR
    J Assoc Physicians India; 1991 Mar; 39(3):251-3. PubMed ID: 1880092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The in-vivo activity of co-amoxiclav with netilmicin against experimental methicillin and gentamicin resistant Staphylococcus epidermidis infection in rabbits.
    Chavanet P; Collin F; Muggeo E; Gagelin B; Chassin P; Kosmidis V; Bernard A; Kistermann JP; Portier H
    J Antimicrob Chemother; 1993 Jan; 31(1):129-38. PubMed ID: 8444657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bactericidal effects of co-amoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat.
    Smith GM; Abbott KH; Sutherland R
    J Antimicrob Chemother; 1992 Oct; 30(4):525-34. PubMed ID: 1490922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae.
    Patel JA; Reisner B; Vizirinia N; Owen M; Chonmaitree T; Howie V
    J Pediatr; 1995 May; 126(5 Pt 1):799-806. PubMed ID: 7752010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.
    Boon RJ; Beale AS; Sutherland R
    Antimicrob Agents Chemother; 1986 May; 29(5):838-44. PubMed ID: 3524431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of pulmonary bacterial infections with amoxicillin and clavulanic acid: clinical experience].
    Bisetti A; Grassi L; Romano V; Scacciavillani E
    Arch Monaldi Mal Torace; 1987; 42(6):505-17. PubMed ID: 3334114
    [No Abstract]   [Full Text] [Related]  

  • 50. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
    Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Refractory endodontic lesion associated with Staphylococci aureus.
    Reader CM; Boniface M; Bujanda-Wagner S
    J Endod; 1994 Dec; 20(12):607-9. PubMed ID: 7759989
    [No Abstract]   [Full Text] [Related]  

  • 53. Diversity of methicillin-resistant Staphylococcus aureus isolated in a Canadian hospital.
    Hammerberg O; Bialkowska-Hobrzanska H; Gregson D; McGhie K; Behme R
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):199-205. PubMed ID: 7614960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of influence of beta-lactamase-producing flora on recovery of group A streptococci after treatment of acute pharyngitis.
    Tanz RR; Shulman ST; Sroka PA; Marubio S; Brook I; Yogev R
    J Pediatr; 1990 Dec; 117(6):859-63. PubMed ID: 2123240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage.
    Lewnard JA; Givon-Lavi N; Huppert A; Pettigrew MM; Regev-Yochay G; Dagan R; Weinberger DM
    J Infect Dis; 2016 May; 213(10):1596-605. PubMed ID: 26704617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Staphylococcal osteomyelitis--a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model.
    Gisby J; Beale AS; Bryant JE; Toseland CD
    J Antimicrob Chemother; 1994 Nov; 34(5):755-64. PubMed ID: 7706171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of respiratory tract infections with a combination of amoxycillin and clavulanic acid.
    Karachalios GN
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):647-9. PubMed ID: 4093205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections.
    Brambilla C; Kastanakis S; Knight S; Cunningham K
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):118-24. PubMed ID: 1396725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.